Apex Biotechnology Corp. (TPE:1733)
Taiwan · Delayed Price · Currency is TWD 28.95
-0.05 (-0.17%)
Aug 13, 2025, 1:35 PM CST
Instructure Holdings Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 162.25 | 128 | 115.78 | 181.79 | 202.22 | 94.8 |
Depreciation & Amortization | 61.76 | 63.41 | 74.19 | 92.71 | 94.32 | 103.55 |
Other Amortization | 1.4 | 1.4 | 1.52 | 1.39 | 1.35 | 1.65 |
Asset Writedown & Restructuring Costs | - | - | 17.78 | 6 | - | - |
Loss (Gain) From Sale of Investments | -17.78 | -4.23 | 3.96 | 29.48 | -31.7 | -6.8 |
Stock-Based Compensation | - | - | - | - | 1.59 | - |
Provision & Write-off of Bad Debts | 8.46 | 0.05 | 1.82 | - | -3.5 | -0.36 |
Other Operating Activities | 32.3 | -11.24 | 10.85 | -45.74 | 33.62 | 11.46 |
Change in Accounts Receivable | -62.74 | -58.6 | 188.87 | -1.38 | -160.77 | 110.14 |
Change in Inventory | 136.3 | 67.61 | -17.96 | -116.67 | -136.05 | -9 |
Change in Accounts Payable | -11.22 | 67.96 | -96.22 | -59.51 | 99.31 | -30.54 |
Change in Unearned Revenue | -39.67 | 51.68 | -22.45 | -64.02 | 50.45 | 21.84 |
Change in Other Net Operating Assets | -1.69 | 22.64 | -47.74 | 2.56 | 29.02 | -16.13 |
Operating Cash Flow | 269.36 | 328.67 | 230.39 | 26.62 | 179.87 | 280.6 |
Operating Cash Flow Growth | 1.67% | 42.66% | 765.61% | -85.20% | -35.90% | -39.33% |
Capital Expenditures | -26.24 | -28.24 | -21.91 | -36.58 | -26.59 | -45.25 |
Sale (Purchase) of Intangibles | -1.74 | -1.39 | -3.07 | -4.07 | -3.6 | -3.07 |
Investment in Securities | - | - | - | -0.7 | -2 | 123.19 |
Other Investing Activities | 0.19 | -5.96 | 2.48 | -0.01 | -2.83 | 3.97 |
Investing Cash Flow | -27.8 | -35.6 | -22.5 | -41.37 | -35.02 | 78.83 |
Short-Term Debt Issued | - | 29.45 | 281.16 | 964.61 | 1,690 | 200 |
Total Debt Issued | 17.68 | 29.45 | 281.16 | 964.61 | 1,690 | 200 |
Short-Term Debt Repaid | - | -59.45 | -301.16 | -1,065 | -1,540 | -297.51 |
Long-Term Debt Repaid | - | -8.7 | -8.2 | -7.68 | -404.2 | -5.51 |
Total Debt Repaid | -31.4 | -68.15 | -309.35 | -1,072 | -1,944 | -303.02 |
Net Debt Issued (Repaid) | -13.73 | -38.7 | -28.2 | -107.68 | -254.2 | -103.02 |
Issuance of Common Stock | - | - | - | - | 12.25 | - |
Repurchase of Common Stock | - | - | - | - | - | -12.25 |
Common Dividends Paid | - | -109.95 | -139.93 | -129.94 | -109.32 | -109.95 |
Other Financing Activities | - | -0.03 | -0.02 | 0.01 | -0.01 | 0.36 |
Financing Cash Flow | -13.73 | -148.67 | -168.14 | -237.6 | -351.27 | -224.85 |
Foreign Exchange Rate Adjustments | -9.48 | 6.24 | 10.59 | 28.72 | -25.19 | -1.34 |
Net Cash Flow | 218.35 | 150.64 | 50.34 | -223.63 | -231.61 | 133.25 |
Free Cash Flow | 243.12 | 300.43 | 208.48 | -9.97 | 153.28 | 235.35 |
Free Cash Flow Growth | -1.67% | 44.10% | - | - | -34.87% | -42.23% |
Free Cash Flow Margin | 11.96% | 16.22% | 12.44% | -0.44% | 7.19% | 11.74% |
Free Cash Flow Per Share | 2.42 | 2.99 | 2.08 | -0.10 | 1.45 | 2.08 |
Cash Interest Paid | 3.64 | 3.64 | 4.39 | 5.4 | 4.7 | 5.45 |
Cash Income Tax Paid | 48.43 | 48.43 | 18.9 | 24.04 | 9.19 | 29.54 |
Levered Free Cash Flow | 336.23 | 254.23 | 164.39 | -78.18 | 55.06 | 199.12 |
Unlevered Free Cash Flow | 338.45 | 256.51 | 167.14 | -74.81 | 62.89 | 205.54 |
Change in Working Capital | 20.97 | 151.29 | 4.5 | -239.01 | -118.04 | 76.31 |
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.